We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find out why I rate MRK a Buy.

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

Merck & Co., Inc. (NYSE:MRK) is one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. On July 10, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Merck & Co., Inc is a global healthcare leader company engaged in the discovery, identification, and development of advanced treatment for cancer and various diseases.

Merck & Co. is closing in on an approximately $10 billion deal to acquire respiratory drugmaker Verona Pharma, the Financial Times reported Merck would pay $107 per American depository share for the ...